Testosterone Decanoate vs Undecanoate: One Carbon, Three Times the Half-Life

Testosterone decanoate (10-carbon ester) and injectable testosterone undecanoate (11-carbon ester, sold as Nebido in Europe and Australia and Aveed in the United States) are the two longest esters attached to a testosterone backbone. The single carbon between them does not predict how differently they behave.

Testosterone decanoate has a half-life of approximately 7.5 days. It remains a weekly injectable, reaches steady state in 5 to 6 weeks, and clears in 6 to 7. There is no pharmaceutical standalone product: its licensed use is as the 100 mg sustained fraction of Sustanon 250, and standalone vials are underground lab products.

Testosterone undecanoate (injectable) has a half-life of approximately 20 to 21 days, driven not only by the longer ester but by the castor oil vehicle and the 4 mL depot volume. It is a licensed TRT medicine given every 10 to 14 weeks after a loading injection at week 6, and true steady state takes approximately 30 weeks.

Note: oral testosterone undecanoate (Andriol, Jatenzo) is a completely different preparation with lymphatic absorption and a half-life measured in hours. This comparison covers the injectable form only.

Ester chain length and half-life:

• Decanoate: 10-carbon ester, half-life approximately 7.5 days
• Undecanoate: 11-carbon ester in castor oil, half-life approximately 20 to 21 days
• Undecanoate is nearly 3 times longer-acting despite the single extra carbon. The oil vehicle and the depot volume contribute as much as the ester itself.

Testosterone content by weight:

• Decanoate: approximately 65 mg of testosterone per 100 mg of compound
• Undecanoate: approximately 61 mg per 100 mg
• The closest pair in the family on this measure, and the difference is not clinically meaningful

Injection schedule and volume:

• Decanoate: weekly, typically 0.5 to 1.5 mL of a 200 to 250 mg/mL preparation, IM or subcutaneous at TRT doses
• Undecanoate: 4 mL (1,000 mg) deep intramuscular only, injected over at least two minutes, every 10 to 14 weeks after loading. Aveed carries an FDA-mandated REMS in the United States because of pulmonary oil microembolism risk.

Loading and steady state:

• Decanoate: no loading protocol. Steady state at approximately 5 to 6 weeks.
• Undecanoate: loading injections at week 0 and week 6, then maintenance. True steady state at approximately 30 weeks, during which levels are variable and often below target.

Dose flexibility:

• Decanoate: dose is adjustable at any weekly injection, and the change is fully expressed in 5 to 6 weeks
• Undecanoate: the dose is fixed at 1,000 mg and adjustment happens by shifting the injection interval. The effect of any change takes many weeks to become visible.

Clearance:

• Decanoate: 6 to 7 weeks
• Undecanoate: 3 to 4 months, which makes a structured PCT impractical

Regulatory status:

• Decanoate: no licensed standalone product anywhere. UGL only.
• Undecanoate: licensed first-line TRT in multiple jurisdictions, with published trial data behind the dosing schedule.

Blood draw strategy:

• Decanoate: single trough draw from week 6 onward. The curve is flat enough that draw timing within the week is a minor factor.
• Undecanoate: two draws are informative, one at the midpoint (approximately week 6 of a 12-week interval) and one at trough before the next injection. Both must be recorded against the exact date of the last injection or they cannot be interpreted.

Choose testosterone decanoate for:

• A stable long-run protocol where a weekly injection is acceptable and the dose is already settled
• Users who want a flat curve but need to retain the ability to change the dose within a month or so
• Enhanced protocols, where undecanoate's fixed 1,000 mg dose and multi-month washout are unworkable

Choose testosterone undecanoate for:

• Clinically supervised TRT where injection frequency is the barrier to adherence
• Patients managed in-clinic, where the 4 mL volume and the REMS requirements are handled by the provider
• Anyone who wants a licensed pharmaceutical product rather than a UGL preparation

Neither is appropriate when:

• A defined cycle end and PCT are planned. Decanoate demands a 6 to 7 week washout and undecanoate 3 to 4 months. Both are usually tapered through a shorter ester instead.
• Rapid side effect correction may be needed. Haematocrit or oestradiol problems on either compound are managed by intervention rather than by waiting for a dose reduction to take effect.

Practical distinction: decanoate is the longest ester that still behaves like a normal weekly injectable. Undecanoate is a different category of product with its own loading protocol, injection technique, monitoring strategy, and risk profile. Users tend to reach for decanoate expecting Nebido-style convenience and find they still have a weekly injection to do; the honest gain over cypionate is smoothness, not frequency.